8-(5-fluoro-2-methylphenoxymethyl)-7-(4-hydroxy-2-methoxyphenyl)-1,3,3-trimethyl-3,4-dihydro-1H-quinoxalin-2-one | 949889-94-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 8-(5-fluoro-2-methylphenoxymethyl)-7-(4-hydroxy-2-methoxyphenyl)-1,3,3-trimethyl-3,4-dihydro-1H-quinoxalin-2-one
• 英文别名: 8-[(5-fluoro-2-methylphenoxy)methyl]-7-(4-hydroxy-2-methoxyphenyl)-1,3,3-trimethyl-4H-quinoxalin-2-one
• CAS: 949889-94-5
• 化学式: C₂₆H₂₇FN₂O₄
• 分子量: 450.51
• InChiKey: ISOWIHLLQQKVNP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  33
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  71
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  8-(5-fluoro-2-methylphenoxymethyl)-7-(4-hydroxy-2-methoxyphenyl)-1,3,3-trimethyl-3,4-dihydro-1H-quinoxalin-2-one 在 4-二甲氨基吡啶 、 potassium carbonate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 (S)-7-[4-(2-benzyloxyethanoyloxypropyl)oxy-2-methoxyphenyl]-8-(5-fluoro-2-methylphenoxymethyl)-1,3,3-trimethyl-3,4-dihydro-1H-quinoxalin-2-one
  参考文献：
  名称：

  EP3342768

  摘要：

  公开号：
• 作为产物：
  描述：

  5-氨基-2-溴苯甲酸甲酯 在 bis-triphenylphosphine-palladium(II) chloride 盐酸 、 甲醇 、 lithium aluminium tetrahydride 、 乙醇 、 三丁基膦 、 硫酸 、 三氟化硼乙醚 、 硝酸 、 caesium carbonate 、 三乙胺 、 potassium iodide 、 tin(ll) chloride 、 1,1'-azodicarbonyl-dipiperidine 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 118.33h， 生成 8-(5-fluoro-2-methylphenoxymethyl)-7-(4-hydroxy-2-methoxyphenyl)-1,3,3-trimethyl-3,4-dihydro-1H-quinoxalin-2-one
  参考文献：
  名称：

  GLUCOCORTICOID RECEPTOR AGONIST COMPRISING NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE CONTAINING PHENYL GROUP HAVING SULFONIC ACID ESTER STRUCTURE INTRODUCED THEREIN AS SUBSTITUENT

  摘要：

  该对象旨在发现一种新型的药理活性，该活性来自一种新型的1,2,3,4-四氢喹喔啉衍生物，其中含有一个苯基，其上引入了磺酸酯结构。通式（1）表示的化合物或其盐可用作糖皮质激素受体激动剂，特别是作为治疗剂，用于一些被认为对糖皮质激素受体激动剂（例如类固醇）有效的疾病，例如炎症性骨关节疾病，炎症性眼科疾病（眼睛前段或后段的炎症性眼科疾病）。其中，R1表示通式（2a）、（3a）、（4a）或（5a）表示的基团；R2表示可能有取代基的较低烷基基团、可能有取代基的较低环烷基基团等；R3表示较低烷基基团；R4、R5、R6或R7表示卤素原子、可能有取代基的较低烷基基团、羟基、可能有取代基的较低烷氧基团等；m、n、p或q表示0、1或2的数字。

  公开号：

  EP2327699A1

文献信息

• Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity
  申请人：Matsuda Mamoru

  公开号：US20090111807A1

  公开（公告）日：2009-04-30

  An object of the present invention is to synthesize a novel 1,2,3,4-tetrahydroquinoxaline derivative represented by formula (1) and to find a pharmacological action of the derivative. In the formula, the R 1 represents a halogen, an alkyl, cycloalkyl, aryl or heterocyclic group, or the like; p represents 0 to 5; R 2 represents a halogen, an alkyl, hydroxyl or alkoxy group, or the like; q represents 0 to 2; R 3 represents hydrogen, an alkyl, alkenyl, alkylcarbonyl or arylcarbonyl group, or the like; R 4 and R 5 independently represent hydrogen, a halogen, an alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heterocyclic group, or the like; R 6 represents hydrogen, an alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heterocyclic group, or the like; A represents an alkylene; R 7 represents OR 8 , NR 8 R 9 , SR 8 , S(O)R 8 , S(O) 2 R 8 ; and X represents O or S.

  本发明的目的是合成一种新的1,2,3,4-四氢喹喔啉衍生物，其化学式表示为（1），并找到该衍生物的药理作用。其中，R1代表卤素、烷基、环烷基、芳基或杂环基等；p表示0至5；R2代表卤素、烷基、羟基或烷氧基等；q表示0至2；R3代表氢、烷基、烯基、烷基羰基或芳基羰基等；R4和R5独立地表示氢、卤素、烷基、烯基、炔基、环烷基、芳基或杂环基等；R6代表氢、烷基、烯基、炔基、环烷基、芳基或杂环基等；A代表烷基；R7代表OR8、NR8R9、SR8、S（O）R8、S（O）2R8；X代表O或S。
• GLUCOCORTICOID RECEPTOR AGONIST COMPRISING 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVES CONTAINING PHENYL GROUP HAVING SULFONIC ACID ESTER STRUCTURE INTRODUCED THEREIN AS SUBSTITUENT
  申请人：Kato Masatomo

  公开号：US20110166151A1

  公开（公告）日：2011-07-07

  The object aims to find a novel pharmacological activity of a novel 1,2,3,4-tetrahydroquinoxaline derivative which contains, as a substituent, a phenyl group having a sulfonic acid ester structure introduced therein. A compound represented by general formula (1) or a salt thereof is useful as a glucocorticoid receptor agonist, particularly as a therapeutic agent for diseases against which a glucocorticoid receptor agonist (e.g., a steroid) is believed to be effective, such as inflammatory bone/joint diseases, inflammatory ophthalmic diseases (inflammatory ophthalmic diseases in the anterior or posterior segment of an eye). R 1 represents a group represented by general formula (2a), (3a), (4a) or (5a); R 2 represents a lower alkyl group which may have a substituent, a lower cycloalkyl group which may have a substituent, or the like; R 3 represents a lower alkyl group; R 4 , R 5 , R 6 or R 7 represent a halogen atom, a lower alkyl group which may have a substituent, a hydroxy group, a lower alkoxy group which may have a substituent, or the like; and m, n, p or q represents a number of 0, 1 or 2.

  该对象旨在发现一种新的药理活性，该药理活性是一种含有苯基磺酸酯结构取代基的新型1,2,3,4-四氢喹喔啉衍生物。由通式（1）或其盐所表示的化合物可用作糖皮质激素受体激动剂，特别是用作糖皮质激素受体激动剂（例如类固醇）被认为对其有效的疾病的治疗剂，如炎症性骨关节疾病，炎症性眼病（眼部前后段的炎症性眼病）。其中，R1表示由通式（2a），（3a），（4a）或（5a）表示的基团；R2表示可以具有取代基的较低烷基基团，可以具有取代基的较低环烷基团或类似基团；R3表示较低烷基基团；R4，R5，R6或R7表示卤素原子，可以具有取代基的较低烷基基团，羟基，可以具有取代基的较低烷氧基或类似基团；m，n，p或q表示0,1或2的数字。
• NOVEL 1,2,3,4,-TETRAHYDROQUINOXALINE DERIVATIVE WHICH HAS, AS SUBSTITUENT, PHENYL GROUP HAVING SULFONIC ACID ESTER STRUCTURE OR SULFONIC ACID AMIDE STRUCTURE INTRODUCED TEREIN AND HAS GLUCOCORTICOID RECEPTOR-BINDING ACTIVITY
  申请人：Matsuda Mamoru

  公开号：US20100137307A1

  公开（公告）日：2010-06-03

  The compounds represented in general formula (1) or a salt thereof are useful for glucocorticoid receptor modulators. In the formula, R 1 represents a lower alkyl group, a lower cycloalkyl group, an aryl group and the like; R 2 represents a hydrogen atom, a lower alkyl group and the like; R 3 represents a hydrogen atom, a lower alkyl group and the like; R 4 and R 5 represent a hydrogen atom, a lower alkyl group and the like; R 6 represents a hydrogen atom, a lower alkyl group and the like; R 7 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group and the like; W represents an oxygen atom, a sulfur atom, NR 8 and the like; R 8 represents a hydrogen atom, a lower alkyl group and the like; X represents an oxygen atom or a sulfur atom; Y represents a lower alkylene group and the like; Z represents an oxygen atom, a sulfur atom, NR 9 , OCO or OSO 2 ; R 9 represents a hydrogen atom, a lower alkyl group and the like respectively.

  一般式（1）或其盐所代表的化合物可用于糖皮质激素受体调节剂。在该式中，R1代表低碳基，低环烷基，芳基等；R2代表氢原子，低碳基等；R3代表氢原子，低碳基等；R4和R5代表氢原子，低碳基等；R6代表氢原子，低碳基等；R7代表氢原子，低碳基，低烯基等；W代表氧原子，硫原子，NR8等；R8代表氢原子，低碳基等；X代表氧原子或硫原子；Y代表低碳基亚烷基等；Z代表氧原子，硫原子，NR9，OCO或OSO2；R9分别代表氢原子，低碳基等。
• 1,2,3,4-tetrahydroquinoxaline compound with a phenyl group substituent having a sulfonic acid ester structure or a sulfonic acid amide structure introduced therein and having glucocorticoid receptor-binding activity
  申请人：Santen Pharmaceutical Co., Ltd.

  公开号：US08193187B2

  公开（公告）日：2012-06-05

  The compounds represented in general formula (1) or a salt thereof are useful for glucocorticoid receptor modulators. In the formula, R1 represents a lower alkyl group, a lower cycloalkyl group, an aryl group and the like; R2 represents a hydrogen atom, a lower alkyl group and the like; R3 represents a hydrogen atom, a lower alkyl group and the like; R4 and R5 represent a hydrogen atom, a lower alkyl group and the like; R6 represents a hydrogen atom, a lower alkyl group and the like; R7 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group and the like; W represents an oxygen atom, a sulfur atom, NR8 and the like; R8 represents a hydrogen atom, a lower alkyl group and the like; X represents an oxygen atom or a sulfur atom; Y represents a lower alkylene group and the like; Z represents an oxygen atom, a sulfur atom, NR9, OCO or OSO2; R9 represents a hydrogen atom, a lower alkyl group and the like respectively.

  通式（1）中表示的化合物或其盐对于糖皮质激素受体调节剂是有用的。在该式中，R1表示较低的烷基，较低的环烷基，芳基等；R2表示氢原子，较低的烷基等；R3表示氢原子，较低的烷基等；R4和R5表示氢原子，较低的烷基等；R6表示氢原子，较低的烷基等；R7表示氢原子，较低的烷基，较低的烯基等；W表示氧原子，硫原子，NR8等；R8表示氢原子，较低的烷基等；X表示氧原子或硫原子；Y表示较低的烷基等；Z表示氧原子，硫原子，NR9，OCO或OSO2；R9分别表示氢原子，较低的烷基等。
• Method for treating an inflammatory disease by administering a 1,2,3,4- tetrahydroquinoxaline compound containing a phenyl group having a sulfonic acid ester structure introduced therein as a substituent
  申请人：Kato Masatomo

  公开号：US08664221B2

  公开（公告）日：2014-03-04

  The object aims to find a novel pharmacological activity of a novel 1,2,3,4-tetrahydroquinoxaline derivative which contains, as a substituent, a phenyl group having a sulfonic acid ester structure introduced therein. A compound represented by general formula (1) or a salt thereof is useful as a glucocorticoid receptor agonist, particularly as a therapeutic agent for diseases against which a glucocorticoid receptor agonist (e.g., a steroid) is believed to be effective, such as inflammatory bone/joint diseases, inflammatory ophthalmic diseases (inflammatory ophthalmic diseases in the anterior or posterior segment of an eye). R1 represents a group represented by general formula (2a), (3a), (4a) or (5a); R2 represents a lower alkyl group which may have a substituent, a lower cycloalkyl group which may have a substituent, or the like; R3 represents a lower alkyl group; R4, R5, R6 or R7 represent a halogen atom, a lower alkyl group which may have a substituent, a hydroxy group, a lower alkoxy group which may have a substituent, or the like; and m, n, p or q represents a number of 0, 1 or 2.

  该对象旨在找到一种新型药理活性的新型1,2,3,4-四氢喹喔啉衍生物，其中包含有一个苯基，其具有引入其中的磺酸酯结构的取代基。由一般式（1）表示的化合物或其盐可用作糖皮质激素受体激动剂，特别是用作治疗糖皮质激素受体激动剂（例如类固醇）被认为对其有效的疾病的治疗剂，如炎性骨/关节疾病，炎性眼病（眼的前段或后段的炎性眼病）。其中，R1表示由一般式（2a），（3a），（4a）或（5a）表示的基团；R2表示可具有取代基的较低烷基基团，可具有取代基的较低环烷基团等；R3表示较低烷基基团；R4、R5、R6或R7表示卤素原子、可具有取代基的较低烷基基团、羟基、可具有取代基的较低烷氧基等；m、n、p或q表示0、1或2的数字。